We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

February 3, 2019

Frenetic M&A in Healthcare: Are We Getting Priced Out?

Commentary
Chandana Fitzgerald
&

There has been a constant flurry of announcements, press releases on mergers, acquisitions, investments, partnerships in healthcare over the last year. It is rather disorienting and difficult to keep up with. Is this the crazy consolidation that will result in a level setting in 2019 and 2020? We’ve seen the use of some very dramatic descriptions like ‘seismic shift’ to explain the phenomenon, but we don’t think it is seismic yet if the impact of said M&A is yet to be seen. But one thing is for sure, valuations are skyrocketing, and we’re getting priced out!

The Story So Far

You’ve probably already seen a lot of this. But we’ll give you the gist of it. Some of the biggest mergers and acquisitions of 2018 were:
‍Top acquisitions in 2018 by or of a healthcare organization. Source - HealthXL Platform

The key themes we saw are:

Large Provider Mergers and Acquisitions

UnitedHealth’s aggressive purchase of physician practices and surgery centers, the Optum- Davita merger, the Dignity Health - Catholic Health Initiatives merger, CVS’ purchase of Aetna and Cigna’s of Express Scripts - you get the drift.

CVS will now have access to a large captive market for its PBM through its purchase of Aetna. That could help it compete on a more equal footing with UnitedHealth's OptumRx and Anthem's upcoming PBM, IngenioRx. On that note, Anthem is breaking up with Express Scripts following its partnership with Cigna to focus on building and launching its own PBM, IngenioRx. This wave mostly shows we are trying to move away from reactive inpatient care to more proactive home-based care.

The emerging health entities from the active M&A activity are some of the largest employers in the the USA - and therefore have significant captive populations on which to experiment new health innovation models. This also implies blurring of lines between insurance companies that have traditionally been responsible for ‘paying’ for care and providers for ‘delivering’ it.

Is this a fight to the finish for cheaper healthcare in the USA? Making primary care more accessible and affordable is of utmost importance. Patients can go to CVS’ 1,100 walk-in clinics instead of heading to an ER which is clearly more expensive. They also plan to convert CVS' 9,700 retail store locations to community-based healthcare hubs where patients, especially those with chronic diseases, can access some form of treatment as a complement to their normal primary-care physician visits.

Wait a minute. Sounds too good to be true. Some critics worry this may mean fewer options for the consumer, and higher expenses. Combined companies may control too much of the market and eliminate pricing wars, which we very much need. They may certainly lower spending, make higher revenues, but as the consumer, I may still have to pay the same premium for my health insurance. As a physician, I still need to be kept at work - these mega orgs need to prove they’re controlling health care costs and keeping people at work.

Pharma Mega Mergers and Acquisitions

We have seen pharmaceutical companies partnering with digital health solutions in a bid to enhance their offering and remain competitive, but Roche was one of the first companies to actually acquire after multiple investments in data analytics company Flatiron (we are not including older acquisitions older than 2018). This meant many things to them, including:

Bristol Myers Squibb’s merger with Celgene in Jan 2019 for $74B, thus combining the offerings of these two pharmaceutical giants making them a particularly strong competitor in the oncology and immunology space. There is an opportunity for novel therapies and enhanced research and manufacturing capabilities resulting from a merger like this one. On the flipside, the argument healthcare providers may make about eliminating competition resulting in drug price hikes.

GSK bought Novartis’ Consumer Healthcare business in March 2018 for $13B. Consumer remedies sold over the counter have lower margins than prescription drugs, but, they are typically very well known and durable brands with loyal customers.

It is hard to pick a side - such M&A activity is inevitable, given the deep pockets that some of these companies have, and the need start-ups have for a strong partner to help build and grow their business as well as to bring their offering to a larger audience.

Startups Merging with and Acquiring Other Startups

It’s not just the big fish that are at it. We are increasingly seeing digital health startups flexing their M&A muscle and merging and acquiring other solutions with the aim of bulking out their own offering, gaining access to a larger customer base, achieving clinical and non-clinical milestones faster. or ensuring that the competition doesn’t steal their thunder further down the line. Such mergers may lack the oomph of the larger ones mentioned above, but should we care if impact is greater than price?

Doctolib is an example of the latter. In 2018 we saw the appointment booking company buy their fellow booking solution, MonDocteur. So, what was the push and what was the pull. For a start, the French digital health environment was being served up two very similar solutions. The acquisition allows the new body to hold a consolidated space in France and continue to focus their efforts on scaling beyond into other European geographies (Docolib achieved impressive uptake when they launched in Germany in 2017).

We are also seeing a rise in the startup cohort when it comes to acquiring AI capabilities. The likes of Headspace seem to be taking an approach where they establish themselves with a core health offering that seems a little more familiar to consumers, and then once they have gained confidence in the core offering and are ready to tackle increased scale hedge their bets on AI - as demonstrated by the Headspace acquisition of Alpine AI, allowing them to leverage voice enabled interactions.

Livongo acquired Retrofit and this will give Livongo customers access to Retrofit’s Diabetes Prevention Program. Livongo have also bought, as of 30th Jan, behavioral health app MyStrength for north of $10M. Logisticare acquired Circulation for $44 million to provide a larger reach in non-emergency medical transportation.

Technology Companies Moving into Healthcare

In the summer of 2018, a deal dropped that had a reverberations in many industries, one that you couldn't have missed - Amazon's acquisition of PillPack. We’ll keep this section short because you’ve probably read a lot about this.

PillPack has the basic infrastructure that Amazon needs - Mail-order pharmacy licenses in all 50 states, multiple pharmacy locations and a call center.

What this means for the industry:
What Amazon may need to succeed:  
The Rise of Consumerization: Patient as Payer  

Think of Best Buy, a consumer electronics enterprise’s acquisition of Great Call, a platform that builds products and technologies to help aging consumers live more independent lives. This was an unpredicted play, giving Best Buy a slice of the money in healthcare pie and locking in a huge segment of the population whom they could cater to.

We’d argue that the Amazon-Pill Pack deal fits really well under this bucket too. Consumerization (or the rise of the wellness market, if you will), demands good customer service, convenience and transparency, all of which a brand like Amazon offers.

The purchase of Withings back from Nokia, Fitbit’s acquisition of Twine Health, Medtronic’s acquisition of Nutrino, are all indicative of the desire of the consumer to invest in her own wellness, and also of the rise of patient as payer without the myriad barriers and complexities of the traditional pathways of consuming healthcare.

All said and done, with the current amalgamation of players and their strengths, it is obvious there will be massive shifts in the location and experience of healthcare towards retail and virtual spaces, new alliances will give rise to new businesses and business models, and the industry is bound to change significantly in even just a few years from now.

Image credit:T. Greg McKelvey Jr. MD, MPH-Chief Medical Officer at KenSci

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

What are the best routes to market in DTx?

12th April @ 11:00am EDT

Join us as we discuss what are the most scalable and sustainable routes to market in DTx. Great opportunity to connect with peers and meet new people.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Masterclass - The regulation of DTx

15th April @ 10:30am EDT

Join us in this Masterclass led by Stephen Gibney from BlueBridge Technologies as we discuss the regulation of DTx. Great opportunity to Listen, engage and most importantly, enjoy.

Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Why is Medtech right for DTx and vice versa

22nd April @ 11:30am EDT

Join our Digital Health Meeting as we discuss why Medtech is right for DTx and vice versa. Apply promptly to get involved in the conversation, network with peers and share your thoughts on the topic.

Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Vivian Emmely de Ruijter
Vivian Emmely de Ruijter
Senior Manager, Digital and Technology Group, Manatt Ventures at Manatt, Phelps & Phillips, LLP
Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Vivian Emmely de Ruijter
Vivian Emmely de Ruijter
Senior Manager, Digital and Technology Group, Manatt Ventures at Manatt, Phelps & Phillips, LLP
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

DTx - Overview of market and deals

28th April @ 10:30AM EDT

Join our Digital Health Meeting focused on the overview of market and deals in the DTx industry. Apply promptly to secure your place in the discussion and network with peers.

Featuring
Ethan Wergelis-Isaacson
Ethan Wergelis-Isaacson
Digital Health Strategy & Business Development , Otsuka Pharmaceutical Companies
Featuring
Ethan Wergelis-Isaacson
Ethan Wergelis-Isaacson
Digital Health Strategy & Business Development , Otsuka Pharmaceutical Companies

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

What are the best routes to market in DTx?

12th April @ 11:00am EDT

Join us as we discuss what are the most scalable and sustainable routes to market in DTx. Great opportunity to connect with peers and meet new people.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support

The future of digital medical education

13th April @ 10:30am EDT

Join us as we discuss the future of digital medical education and its impact on digital health adoption. Great opportunity to connect with peers, engage in thought-provoking conversations and meet new people.

Featuring
Joshua Landy MD
Joshua Landy MD
Chief Medical Officer, Figure 1
Meg Barron
Meg Barron
Vice President, Digital Health Strategy, American Medical Association
Featuring
Joshua Landy MD
Joshua Landy MD
Chief Medical Officer, Figure 1
Meg Barron
Meg Barron
Vice President, Digital Health Strategy, American Medical Association
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support

Role of digital patient communities in 2021

14th April @ 10:30am EDT

Join our Digital Health Meeting as we discuss the role of digital patient communities in 2021. Apply now to secure your place in the conversation and gain valuable insights from thought leaders in the industry.

Featuring
Chelsea Pan
Chelsea Pan
Partnership Engagement Manager, Verily Life Sciences
Carlos Rodarte
Carlos Rodarte
Founder & Managing Director, Volar Health LLC
Featuring
Chelsea Pan
Chelsea Pan
Partnership Engagement Manager, Verily Life Sciences
Carlos Rodarte
Carlos Rodarte
Founder & Managing Director, Volar Health LLC
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Masterclass - The regulation of DTx

15th April @ 10:30am EDT

Join us in this Masterclass led by Stephen Gibney from BlueBridge Technologies as we discuss the regulation of DTx. Great opportunity to Listen, engage and most importantly, enjoy.

Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.